Cara Janusz to Cost-Benefit Analysis
This is a "connection" page, showing publications Cara Janusz has written about Cost-Benefit Analysis.
Connection Strength
0.429
-
Janusz CB, Wagner AL, Masters NB, Ding Y, Zhang Y, Hutton DW, Boulton ML. Measles vaccination of young infants in China: A cost-effectiveness analysis. Vaccine. 2020 Jun 15; 38(29):4616-4624.
Score: 0.172
-
Aguilar IB, Mendoza LO, García O, Díaz I, Figueroa J, Duarte RM, Perdomo G, Garcia AG, Janusz CB. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras. Vaccine. 2015 May 07; 33 Suppl 1:A167-73.
Score: 0.121
-
Yeung KHT, Lin SL, Clark A, McGhee SM, Janusz CB, Atherly D, Chan KC, Nelson EAS. Economic evaluation of the introduction of rotavirus vaccine in Hong Kong. Vaccine. 2021 Jan 03; 39(1):45-58.
Score: 0.045
-
Kieninger MP, Caballero EG, Sosa AA, Amarilla CT, Jáuregui B, Janusz CB, Clark AD, Castellanos RM. Cost-effectiveness analysis of pneumococcal conjugate vaccine introduction in Paraguay. Vaccine. 2015 May 07; 33 Suppl 1:A143-53.
Score: 0.030
-
Mezones-Holguin E, Canelo-Aybar C, Clark AD, Janusz CB, Jaúregui B, Escobedo-Palza S, Hernandez AV, Vega-Porras D, González M, Fiestas F, Toledo W, Michel F, Suárez VJ. Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru. Vaccine. 2015 May 07; 33 Suppl 1:A154-66.
Score: 0.030
-
Walwyn L, Janusz CB, Clark AD, Prieto E, Waight E, Largaespada N. Cost-effectiveness of HPV vaccination in Belize. Vaccine. 2015 May 07; 33 Suppl 1:A174-81.
Score: 0.030